PreOperative Treatment With chEmotheRapy or chemoRAdiatioN in esophaGeal or gastroEsophageal adenocaRcinoma
The best treatment for resectable esophageal cancer or cancer between esophagus and stomach
(GE junction) is unknown. Although an operation to remove the esophagus is the most common
treatment, previous studies have shown that patients live longer when either chemotherapy or
chemotherapy plus radiation (chemoradiation) is given before surgery (preoperative),
compared to surgery alone. However it is unknown which of these treatments (preoperative
chemotherapy or preoperative chemoradiation) is more effective in improving survival. A
study where patients with resectable esophageal / GE junction cancer are chosen at random to
receive one of the two preoperative treatments would help determine if one form of treatment
improves survival compared to the other.
Patients with localized esophageal / GE junction cancer (adenocarcinoma) will be randomized
to receive either preoperative chemotherapy or preoperative chemoradiation followed by
The main objective of this pilot trial is to determine the possibility of conducting a
larger study with many centres participating. If this study proves to be feasible with
enough patients enrolled and able to tolerate treatments without major side effects then we
can hopefully proceed to perform a larger multi-centre trial to look for survival outcome
differences between patients who receive preoperative chemotherapy and those who receive
preoperative chemoradiation. The results of this trial would ultimately help us choose the
most effective treatment of resectable esophageal cancer and hopefully improve survival.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society